Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib for refractory rare immune-mediated inflammatory diseases
NL-OMON60703Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgotinib in Behçet's disease (BD), Autoimmune Myopathies and IgG4-related disease (IgG4-RD), sponsored by University Medical Center Utrecht. Primary endpoint: EuroQol 5D-5L. Planned start Apr 2023; status: withdrawn.
02
Drugs
filgotinib
03
Conditions
Behçet's disease (BD)Autoimmune MyopathiesIgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NL-OMON60703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60703.